Loading...
Beam Therapeutics Community
NasdaqGS:BEAM Community- 2 Narratives written by author
- 3 Comments on narratives written by author
- 104 Fair Values set on narratives written by author
Community Investing Ideas
The "Molecular Pencil": Why Beam's Technology is Built to Win
The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Read more
11users have liked this narrative
3users have commented on this narrative
50users have followed this narrative
DA
US$150
81.9% undervalued intrinsic discount
davidlsander Fair Value
Revenue
295.2% p.a.
Profit Margin
21.34%
Future PE
30.21x
Price in 2028
US$183.38
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
Key Takeaways Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential. Strategic advancements in gene editing could expand patient access and drive revenue growth through broader treatment availability.Read more
0users have liked this narrative
0users have commented on this narrative
48users have followed this narrative
AN
US$45.92
41.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
13.91% p.a.
Profit Margin
16.06%
Future PE
469.09x
Price in 2028
US$55.74
